National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Guidelines for the Prevention, Detection, and Management of Heart Failure in Australia 2018

Atherton, J.; Sindone, Andrew; Pasquale, Carmine G. De; Driscoll, Andrea; Macdonald, P.; Hopper, Ingrid; Kistler, Peter M.; Briffa, Tom; Wong, J.; Abhayaratna, Walter P.; Thomas, Liza; Audehm, Ralph; Newton, Phillip J.; O'Loughlin, J; Branagan, Marie; Connell, Cia

doi:10.1016/j.hlc.2018.06.1042

Cited by 293 publications

(340 citation statements)

References 599 publications

(633 reference statements)

Supporting

Mentioning

336

Contrasting

Unclassified

Order By: Relevance

“…The single most useful investigation is the echocardiogram. However, if the diagnosis is unclear and an echocardiogram cannot be arranged in a timely fashion, measurement of either plasma BNP or N‐terminal proBNP has been shown to improve diagnostic accuracy 2 ► Practice point : Evaluation of coronary arteries should be guided by the presence or absence of symptoms of coronary artery disease and the pre‐test probability of coronary artery disease. ► Practice point : Box 3 lists red flags where early specialist referral may be considered.…”

Section: Methodsmentioning

confidence: 99%

“…The management of acute HF should be guided by the patient's vital signs, oxygen saturation, and the presence or absence of congestion and hypoperfusion. Management includes intravenous diuretics in most patients accompanied by the selected use of oxygen therapy (if hypoxaemic), positive pressure ventilation, vasodilators and inotropes 2 . Effective long term management of HF is key to decreasing hospitalisation and improving survival.…”

Section: Methodsmentioning

confidence: 99%

“…This executive summary provides important recommendations together with their strength of evidence and guidance for their implementation in clinical practice (practice points). The full clinical guidelines are available in Heart, Lung and Circulation at https://protect-au.mimecast.com/s/PjtXCE8k3OTVl0JiN4hmP?domain=doi.org 2 …”

mentioning

confidence: 99%

See 2 more Smart Citations

National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the management of heart failure 2018

Atherton

Sindone

Pasquale

et al. 2018

Medical Journal of Australia

Self Cite

View full text Add to dashboard Cite

Introduction: Heart failure (HF) is a clinical syndrome that is secondary to an abnormality of cardiac structure or function. These clinical practice guidelines focus on the diagnosis and management of HF with recommendations that have been graded on the strength of evidence and the likely absolute benefit versus harm. Additional considerations are presented as practice points. Main recommendations: Blood pressure and lipid lowering decrease the risk of developing HF. Sodium–glucose cotransporter 2 inhibitors decrease the risk of HF hospitalisation in patients with type 2 diabetes and cardiovascular disease. An echocardiogram is recommended if HF is suspected or newly diagnosed. If an echocardiogram cannot be arranged in a timely fashion, measurement of plasma B‐type natriuretic peptides improves diagnostic accuracy. Angiotensin‐converting enzyme inhibitors, β‐blockers and mineralocorticoid receptor antagonists improve outcomes in patients with HF associated with a reduced left ventricular ejection fraction. Additional treatment options in selected patients with persistent HF associated with reduced left ventricular ejection fraction include switching the angiotensin‐converting enzyme inhibitor to an angiotensin receptor neprilysin inhibitor; ivabradine; implantable cardioverter defibrillators; cardiac resynchronisation therapy; and atrial fibrillation ablation. Multidisciplinary HF disease management facilitates the implementation of evidence‐based HF therapies. Clinicians should also consider models of care that optimise medication titration (eg, nurse‐led titration). Changes in management as a result of the guideline: These guidelines have been designed to facilitate the systematic integration of recommendations into HF care. This should include ongoing audit and feedback systems integrated into work practices in order to improve the quality of care and outcomes of patients with HF.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the management of heart failure 2018

Atherton

Sindone

Pasquale

et al. 2018

Medical Journal of Australia

Self Cite

View full text Add to dashboard Cite

show abstract

“…In the 2017 American College of Cardiology/American Heart Association/Heart Failure Society of America (ACC/AHA/HFSA) focused update of the 2013 ACC/AHA guideline for the management of HF, SGLT2 inhibitors were not mentioned . In the 2018 guidelines for the prevention, detection and management of HF in Australia, SGLT2 inhibitors are recommended in patients with T2DM associated with CV disease and poor glycaemic control (on top of metformin), to decrease the risk of CV events and HF hospitalization. Recently, in the 2019 American Diabetes Association Standards of Medical Care in Diabetes, SGLT2 inhibitors are recommended for the first time as a treatment of choice in patients with T2DM and HF, as well as in those with chronic kidney disease.…”

Section: The Backgroundmentioning

confidence: 99%

News from the American Heart Association: more on sodium–glucose co‐transporter 2 inhibitors, diabetes and heart failure

Coats

Seferović²

2019

European J of Heart Fail

View full text Add to dashboard Cite

“…However, more confusion has arisen as a result of concerns expressed recently in the literature as to whether the characteristics and prognosis justify the creation of a separate HF entity. An example is the Australian HF guidelines of 2018, which again suggested that patients with this intermediate category of EF should be differentiated only from those with EF > 50% and grouped with HFrEF patients, as before. Consequently, there is an urgent need to collect further clinical data that will help us better establish the clinical value of treating patients with EF 40%‐49% as a separate category and the optimal approach to their management in comparison with the other two HF groups.…”

Section: Introductionmentioning

confidence: 99%

Long‐term outcome of hypertensive patients with heart failure with mid‐range ejection fraction: The significance of blood pressure control

Marketou

Maragkoudakis

Fragiadakis

et al. 2019

J of Clinical Hypertension

View full text Add to dashboard Cite

Heart failure (HF) with mid‐range ejection fraction (HFmrEF) is a newly suggested entity in HF. Since it has been inadequately addressed, there is an urgent need to determine the profile of HFmrEF patients and the optimal approach to their management. The present study aimed to assess the long‐term clinical outcomes of hypertensive patients with HFmrEF and the impact of blood pressure (BP) on their mortality and cardiovascular outcome. We performed a retrospective observational study that included 121 hypertensive patients with HFmrEF and 149 hypertensives with heart failure and preserved ejection fraction (HFpEF). The median follow‐up was 84 months (22‐122). Our analysis did not reveal any statistically significant difference between the two groups in total mortality (P = 0.34) or cardiovascular mortality (P = 0.54). The total mean survival time was 102.9 months (100.5‐110.1), while the mean survival time was 105.3 months (80.4‐90.2) in HFpEF and 97.6 months (92.7‐102.6) in HFmrEF. An office systolic BP > 139 mm Hg and diastolic BP > 89 mm Hg were significantly associated with both all‐cause mortality (P = 0.02 and P = 0.013, respectively) and cardiovascular mortality (P = 0.02 for both). In HFpEF patients, no significant association was found between outcome and office BP. HFpEF and HFmrEF have similar long‐term outcomes. Suboptimal BP levels are a significant risk factor for an adverse outcome in HFmrEF. Our results emphasize the importance of good BP control in order to achieve better outcomes in hypertensives with impaired EF and HF symptomatology.

show abstract

National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Guidelines for the Prevention, Detection, and Management of Heart Failure in Australia 2018

Cited by 293 publications

References 599 publications

National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the management of heart failure 2018

National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the management of heart failure 2018

News from the American Heart Association: more on sodium–glucose co‐transporter 2 inhibitors, diabetes and heart failure

Long‐term outcome of hypertensive patients with heart failure with mid‐range ejection fraction: The significance of blood pressure control

Contact Info

Product

Resources

About